New Venture Challenge

NewVenture Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology and inflammatory diseases. The company leverages a proprietary structure-based drug discovery platform to design highly selective inhibitors targeting the Janus kinase (JAK) family and other key signaling pathways. Its lead candidate, NV0101, is a selective JAK1 inhibitor currently in Phase 2 clinical trials for indications such as atopic dermatitis and rheumatoid arthritis. NewVenture Pharma aims to address significant unmet medical needs by providing safer and more effective treatment options for patients with chronic autoimmune and inflammatory conditions.